Related Experiment Video
Updated: Jul 28, 2026

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?
C J Vaughan1, N Delanty, C T Basson
1Division of Cardiology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA.
Insights
Statins, or beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, offer neuroprotection and reduce stroke risk. Their benefits may stem from stabilizing plaques, antithrombotic actions, and cholesterol-independent pathways like interrupting isoprenoid biosynthesis.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Emerging evidence suggests statins provide neuroprotection beyond reducing ischemic stroke.
- Statins are known to reduce stroke incidence via plaque stabilization and antithrombotic effects.
Purpose of the Study:
- To explore the neuroprotective mechanisms of statins.
- To investigate the role of statins in cerebrovascular disease and dementia prevention.
Main Methods:
- Review of current evidence on statin mechanisms.
- Analysis of cholesterol-dependent and independent neuroprotective pathways.
Main Results:
- Statins exhibit neuroprotective effects, potentially through interrupting isoprenoid biosynthesis.
- Statin therapy may preserve endothelial nitric oxide synthase activity and blood flow in ischemic regions.
- Anti-inflammatory and antioxidant properties of statins contribute to neuroprotection.
Conclusions:
- Statins offer significant neuroprotection, with mechanisms including cholesterol-independent pathways.
- Further clinical trials are needed to confirm statin efficacy in primary stroke prevention, small vessel disease, and vascular dementia.
Abstract:
An emerging body of evidence indicates that beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or 'statins', provide neuroprotection in addition to reducing ischaemic stroke. Statins reduce the incidence of ischaemic stroke by stabilising atherosclerotic plaques in the precerebral vasculature and through antithrombotic actions, and the neuroprotective effects of statins may confer significant clinical benefit. Some of these neuroprotective effects are likely to be cholesterol independent and mediated by the interruption of isoprenoid biosynthesis. Therapy with statins may modulate endothelial function and preserve blood flow to regions exposed to an ischaemic insult. In particular, statin-mediated preservation of endothelial nitric oxide synthase activity in cerebral vasculature, especially in the ischaemic penumbra, may limit neurological deficit. Moreover, putative anti-inflammatory and antioxidant properties of statins may confer additional neuroprotection. Further large clinical trials are necessary to address the role of statin therapy in the primary prevention of stroke, small vessel cerebrovascular disease and vascular dementia.
More Related Videos
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
07:34Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
Published on: December 15, 2023
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Atherosclerosis III: Management
Stroke: Introduction and Types
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology